Alnylam Pharmaceuticals (NASDAQ:ALNY) Director Sells $13,729,567.84 in Stock

Key Points

• Dennis A. Ausiello, Director of Alnylam Pharmaceuticals, sold 31,448 shares at an average price of $436.58, significantly reducing his ownership by 97.18%.
• Alnylam Pharmaceuticals reported a surprise earnings per share (EPS) of $0.32, beating the consensus estimate of ($0.54), reflecting a 17.3% year-over-year revenue increase.
• Institutional investors hold 92.97% of Alnylam's stock, with several firms increasing their stakes, indicating strong institutional interest in the company.

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Get Free Report) Director Dennis A. Ausiello sold 31,448 shares of the firm's stock in a transaction that occurred on Thursday, August 14th. The shares were sold at an average price of $436.58, for a total value of $13,729,567.84. Following the completion of the sale, the director directly owned 911 shares of the company's stock, valued at $397,724.38. This trade represents a 97.18% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.

Alnylam Pharmaceuticals Stock Up 0.3%

Alnylam Pharmaceuticals stock traded up $1.1920 during mid-day trading on Wednesday, reaching $459.4720. The stock had a trading volume of 52,822 shares, compared to its average volume of 952,105. The company has a debt-to-equity ratio of 4.10, a quick ratio of 2.75 and a current ratio of 2.80. Alnylam Pharmaceuticals, Inc. has a fifty-two week low of $205.87 and a fifty-two week high of $462.88. The stock's 50-day simple moving average is $351.27 and its 200-day simple moving average is $292.97. The firm has a market capitalization of $60.23 billion, a PE ratio of -185.56 and a beta of 0.25.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last announced its quarterly earnings data on Thursday, July 31st. The biopharmaceutical company reported $0.32 EPS for the quarter, beating analysts' consensus estimates of ($0.54) by $0.86. Alnylam Pharmaceuticals had a negative return on equity of 273.52% and a negative net margin of 12.96%.The firm had revenue of $773,689 billion during the quarter, compared to analysts' expectations of $633.54 million. During the same quarter last year, the firm posted ($0.13) earnings per share. The company's revenue for the quarter was up 17.3% compared to the same quarter last year. Alnylam Pharmaceuticals has set its FY 2025 guidance at EPS. On average, sell-side analysts forecast that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current fiscal year.

Hedge Funds Weigh In On Alnylam Pharmaceuticals

A number of hedge funds and other institutional investors have recently modified their holdings of ALNY. Atlantic Union Bankshares Corp bought a new stake in shares of Alnylam Pharmaceuticals in the 2nd quarter valued at about $30,000. SVB Wealth LLC bought a new stake in shares of Alnylam Pharmaceuticals in the 1st quarter valued at about $27,000. Whipplewood Advisors LLC lifted its stake in shares of Alnylam Pharmaceuticals by 208.8% in the 1st quarter. Whipplewood Advisors LLC now owns 105 shares of the biopharmaceutical company's stock valued at $28,000 after acquiring an additional 71 shares during the last quarter. Bessemer Group Inc. lifted its stake in shares of Alnylam Pharmaceuticals by 176.9% in the 1st quarter. Bessemer Group Inc. now owns 108 shares of the biopharmaceutical company's stock valued at $29,000 after acquiring an additional 69 shares during the last quarter. Finally, Elevation Point Wealth Partners LLC bought a new stake in shares of Alnylam Pharmaceuticals in the 2nd quarter valued at about $37,000. 92.97% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several research analysts recently issued reports on the company. BMO Capital Markets lifted their target price on Alnylam Pharmaceuticals from $300.00 to $360.00 and gave the company an "outperform" rating in a research report on Tuesday, June 24th. Raymond James Financial assumed coverage on Alnylam Pharmaceuticals in a research note on Wednesday, July 30th. They issued an "outperform" rating and a $370.00 target price on the stock. Piper Sandler boosted their target price on Alnylam Pharmaceuticals from $304.00 to $449.00 and gave the company an "overweight" rating in a research note on Friday, August 1st. Needham & Company LLC boosted their target price on Alnylam Pharmaceuticals from $377.00 to $478.00 and gave the company a "buy" rating in a research note on Thursday, July 31st. Finally, Oppenheimer upgraded Alnylam Pharmaceuticals from a "market perform" rating to an "outperform" rating and set a $490.00 target price on the stock in a research note on Monday, August 4th. Twenty-two research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company's stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $405.33.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.